山东新华医疗器械股份有限公司股权激励限制性股票回购注销实施公告

Group 1 - The company plans to repurchase and cancel a total of 33,370 restricted stocks due to changes in employment status of six incentive recipients, including retirement and job transfers [2][6][7] - The repurchase price is set at 7.55 yuan per share, with interest calculated based on the People's Bank of China's benchmark deposit rate at the time of repurchase [5][6] - Following the cancellation, the company's total share capital will decrease from 606,677,919 shares to 606,644,549 shares [8] Group 2 - The company has received medical device registration certificates for two products: the Interleukin-6 test kit and the Procalcitonin/Interleukin-6 dual test kit, both approved on December 24, 2025 [12][13][16] - The products are designed for quantitative detection of Interleukin-6 and Procalcitonin levels in human blood, plasma, and serum, which are critical in assessing infection severity [15][19] - The introduction of these products enhances the company's competitiveness in the in vitro diagnostic market, providing a variety of options for customers [20]